## Pramila Rijal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6804867/publications.pdf

Version: 2024-02-01

40 papers

2,534 citations

430874 18 h-index 276875 41 g-index

65 all docs

65
docs citations

65 times ranked 5227 citing authors

#	Article	IF	CITATIONS
1	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nature Structural and Molecular Biology, 2020, 27, 846-854.	8.2	434
2	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host and Microbe, 2020, 28, 445-454.e6.	11.0	298
3	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural and Molecular Biology, 2020, 27, 950-958.	8.2	268
4	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature Communications, 2021, 12, 542.	12.8	200
5	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	28.9	173
6	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	12.8	150
7	Focused antibody response to influenza linked to antigenic drift. Journal of Clinical Investigation, 2015, 125, 2631-2645.	8.2	124
8	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. Cell Reports, 2019, 27, 172-186.e7.	6.4	69
9	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathogens, 2021, 17, e1009352.	4.7	56
10	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	12.8	54
11	Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation. Angewandte Chemie - International Edition, 2021, 60, 321-330.	13.8	45
12	Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites. Immunity, 2022, 55, 718-733.e8.	14.3	44
13	Structure–function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans. Nature Microbiology, 2019, 4, 306-315.	13.3	41
14	Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2–Restricted T Cell Epitopes. Journal of Immunology, 2014, 193, 4803-4813.	0.8	40
15	Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans. Journal of Virology, 2020, 94, .	3.4	29
16	A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy. MAbs, 2020, 12, 1804241.	5.2	28
17	Inclusion of cGAMP within virusâ€like particle vaccines enhances their immunogenicity. EMBO Reports, 2021, 22, e52447.	4.5	24
18	Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms. Journal of Immunology, 2020, 205, 648-660.	0.8	22

#	Article	IF	CITATIONS
19	Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. Journal of Virology, 2018, 92, .	3.4	21
20	Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell–cell fusion. Journal of General Virology, 2021, 102, .	2.9	21
21	Persistence of immune responses to the Sinopharm/BBIBPâ€CorV vaccine. Immunity, Inflammation and Disease, 2022, 10, .	2.7	20
22	Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. Frontiers in Immunology, 2018, 9, 865.	4.8	19
23	Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans. PLoS Pathogens, 2021, 17, e1009330.	4.7	13
24	Characterization of neutralizing epitopes in antigenic site B of recently circulating influenza A(H3N2) viruses. Journal of General Virology, 2018, 99, 1001-1011.	2.9	13
25	Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus. MBio, 2020, $11$ , .	4.1	12
26	Fc-Mediated Functions of Porcine IgG Subclasses. Frontiers in Immunology, 0, 13, .	4.8	12
27	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	3.3	11
28	Spatial, temporal and molecular dynamics of swine influenza virus-specific CD8 tissue resident memory T cells. Mucosal Immunology, 2022, 15, 428-442.	6.0	9
29	Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation. Angewandte Chemie, 2021, 133, 325-334.	2.0	8
30	A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge. Journal of General Virology, 2019, 100, 431-445.	2.9	8
31	Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Frontiers in Public Health, 2021, 9, 724398.	2.7	8
32	Immune responses to Sinopharm/ <scp>BBIBPâ€CorV</scp> in individuals in Sri Lanka. Immunology, 2022, 167, 275-285.	4.4	8
33	Lung-targeting lentiviral vector for passive immunisation against influenza. Thorax, 2020, 75, 1112-1115.	5.6	7
34	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics, 2022, 12, 1-17.	10.0	6
35	Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals. Immunity, Inflammation and Disease, 2022, 10, e592.	2.7	6
36	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka. Journal of Immunology, 2021, 207, 2681-2687.	0.8	4

#	Article	IF	CITATION
37	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	4.2	3
38	Low Dose Pig Anti-Influenza Virus Monoclonal Antibodies Reduce Lung Pathology but Do Not Prevent Virus Shedding. Frontiers in Immunology, 2021, 12, 790918.	4.8	3
39	Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay. Tropical Medicine and Infectious Disease, 2021, 6, 155.	2.3	2
40	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. SSRN Electronic Journal, 0, , .	0.4	0